Presentation at the American Epilepsy Society Annual Meeting will also highlight proposed design of planned Phase 3 study of radiprodil in children with gain-of-function variants NEW YORK, Nov. 21, 2024 /PRNewswire/ -- GRIN Therapeutics Inc., a leader in development of therapies to treat...
GRIN Therapeutics to Present Data from Honeycomb Trial of Investigational Radiprodil in GRIN-Related Neurodevelopmental Disorder
Seaking AlphaSeeking Alpha / Seaking Alpha 5 hours ago 1 Views
Comments